Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
MDC-CAR-BCMA001
i
Other names:
MDC-CAR-BCMA001
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Dresden University of Technology, German Cancer Research Center
Drug class:
BCMA-targeted CAR-T immunotherapy
Related drugs:
‹
idecabtagene vicleucel (2)
CB-011 (2)
ciltacabtagene autoleucel (2)
ACLX-001 (1)
ALLO-605 (1)
ALLO-715 (1)
AZD0120 (1)
equecabtagene autoleucel (1)
PBCAR269A (1)
bb21217 (1)
AUTO2 (0)
Autologous CAR-T cells (0)
BCMA CAR-T cell therapy (0)
BCMA targeted CAR T (0)
BCMA targeted CAR T-cells (0)
BCMA-BCL2L1-CART (0)
BCMA-PD1-CART Cells (0)
BMS-986354 (0)
CART-138/BCMA/19/more (0)
CART-BCMA/CS1 (0)
CD19/BCMA targeted CAR T-cells (0)
CTX120 (0)
CYAD-211 (0)
Descartes-08 (0)
FCARH143 (0)
FHVH-BCMA-T (0)
IBI346 (0)
KITE-585 (0)
MCARH125 (0)
MCM998 (0)
MTV273 (0)
OriC321 (0)
P-BCMA-101 (0)
RG6538 (0)
CART-ddBCMA (0)
anti-BCMA CAR-T cells (0)
ARI0002h (0)
PHE885 (0)
multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)
JCARH125 (0)
senl_BCMA (0)
CT053 (0)
idecabtagene vicleucel (2)
CB-011 (2)
ciltacabtagene autoleucel (2)
ACLX-001 (1)
ALLO-605 (1)
ALLO-715 (1)
AZD0120 (1)
equecabtagene autoleucel (1)
PBCAR269A (1)
bb21217 (1)
AUTO2 (0)
Autologous CAR-T cells (0)
BCMA CAR-T cell therapy (0)
BCMA targeted CAR T (0)
BCMA targeted CAR T-cells (0)
BCMA-BCL2L1-CART (0)
BCMA-PD1-CART Cells (0)
BMS-986354 (0)
CART-138/BCMA/19/more (0)
CART-BCMA/CS1 (0)
CD19/BCMA targeted CAR T-cells (0)
CTX120 (0)
CYAD-211 (0)
Descartes-08 (0)
FCARH143 (0)
FHVH-BCMA-T (0)
IBI346 (0)
KITE-585 (0)
MCARH125 (0)
MCM998 (0)
MTV273 (0)
OriC321 (0)
P-BCMA-101 (0)
RG6538 (0)
CART-ddBCMA (0)
anti-BCMA CAR-T cells (0)
ARI0002h (0)
PHE885 (0)
multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)
JCARH125 (0)
senl_BCMA (0)
CT053 (0)
›
Associations
News
Trials
Filter by
Latest
10ms
CARLOTTA01: A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies (clinicaltrials.gov)
P1, N=16, Recruiting, Technische Universität Dresden | Not yet recruiting --> Recruiting
10 months ago
Enrollment open • CAR T-Cell Therapy
|
CD31 (Platelet and endothelial cell adhesion molecule 1) • SLAMF7 (SLAM Family Member 7)
|
CD38 positive
|
MDC-CAR-BCMA001
1year
CARLOTTA01: A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies (clinicaltrials.gov)
P1, N=16, Not yet recruiting, Technische Universität Dresden | Initiation date: Jul 2023 --> Dec 2023
1 year ago
Trial initiation date • CAR T-Cell Therapy
|
CD31 (Platelet and endothelial cell adhesion molecule 1) • SLAMF7 (SLAM Family Member 7)
|
CD38 positive
|
MDC-CAR-BCMA001
over1year
CARLOTTA01: A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies (clinicaltrials.gov)
P1, N=16, Not yet recruiting, Technische Universität Dresden
over 1 year ago
New P1 trial • CAR T-Cell Therapy
|
CD31 (Platelet and endothelial cell adhesion molecule 1) • SLAMF7 (SLAM Family Member 7)
|
CD38 positive
|
MDC-CAR-BCMA001
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login